CClinicalTrials.gg
Status unknownNCT05337865TOPUpdated Apr 20, 2022

Transgender Observational Performance

An observational study in Transgender Persons, sponsored by Instituto Brasileiro de Controle do Cancer. Status unknown. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-20.

Sponsored by Instituto Brasileiro de Controle do Cancer · Observational

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The study will evaluate the sports capabilities of transgender women mainly in terms of muscular strength and aerobic capacity (VO2max). The control group will be composed of cisgender women and cisgender men with the same levels of physical activity.

02

Conditions studied

  • Transgender Persons

Keywords

  • Transgender women
  • Oxygen uptake
  • Cardiac output
  • Muscle strength
  • Acute physical effort
03

In context

Lead sponsor

Instituto Brasileiro de Controle do Cancer is the lead sponsor of 12 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Well-trained Transgender women, cisgender men and cisgender women.

Inclusion criteria

  • Diagnosis of a transgender woman by the DSM-V or ICD10.
  • Gonadectomized and non-gonadectomized
  • Initiation of androgen blockade and/or estrogen use after 12 years of age.
  • Age range 18 to 50 years old.
  • BMI: 18.0 to 34.9 kg/m2.
  • Well-trained individuals (IPAQ very active)

Exclusion criteria

Exclusion Criteria:

  • Current or previous morbidities that could interfere with strength or aerobic tests.
  • Chronic illnesses and/or chronic medication use.
  • Musculoskeletal limitations.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Transgender women

    Well-trained transgender women.

    Other: Aerobic exercise test.

  • Cisgender Women

    Well-trained cisgender women.

    Other: Aerobic exercise test.

  • Cisgender Men

    Well-trained cisgender men.

    Other: Aerobic exercise test.

Interventions

  • OtherAerobic exercise test.

    Aerobic exercise test at a treadmill.

06

What researchers measure

Primary outcomes

  1. Aerobic capacity change of transgender women over 12 months assessed by cardiopulmonary exercise testing (K5 - COSMED, Italia) on a treadmill (MOVEMENT/ET20 RT250G2SAC110V ) with incremental effort until exhaustion (ramp protocol).

    The comparison of changes in aerobic capacity of transgender women, cigender women and cisgender men submitted to maximum effort Participants will be submitted to cardiopulmonary exercise testing (K5 - COSMED, Italia) on a treadmill (MOVEMENT/ET20 RT250G2SAC110V ) with incremental effort until exhaustion (ramp protocol). The maximum functional capacity will be determined by peak oxygen consumption (VO2peak) evaluated at the maximum exercise intensity.

    Time frame: Baseline, 6 months, 12 months after starting the observational study.

Secondary outcomes

  1. Skeletal muscle mass change of transgender women over 12 months assessed by a densitometry device (GE Prodigy).

    The comparison of changes in skeletal muscle mass (kg) of transgender women, cisgender women and cisgender men over 12 months. Muscle mass will be assessed by a densitometry device (GE Prodigy) with X-ray absorptiometry technique with two whole-body energy levels and analyzed in the corresponding manufacturer's software.

    Time frame: Baseline, 6 months, 12 months after starting the observational study.

  2. Muscle strength change of transgender women over 12 months assessed by hand grip strength (HGS) test using the Jamar Hand Dynamometer

    The comparison of changes in muscle strength of transgender women, cisgender women and cisgender men over 12 months. The hand grip strength (HGS) test will be carried out using the Jamar Hand Dynamometer by technique recommended by the American Society of Hand Therapists (ASHT) The tests will be performed with the dominant and non-dominant hands of each individual three consecutive times. Participants will be instructed to perform a maximum contraction for 3 seconds in each test. There will be a 30-second rest period between each test. To analyse the parameters associated with the measurement of HGS in each individual, the mean values (kg) of the three tests for each hand will be used according to the ASHT reference and considered the most reliable way to measure HGS. The maximum strength (kg) of each individual will be also analysed.

    Time frame: Baseline, 6 months, 12 months after starting the observational study.

  3. Vertical jump height changes of transgender women over 12 months assessed by the jumping mat (Elite Jump®, S2 Sports, São Paulo, Brazil)

    The comparison of changes in vertical jump during sprint of transgender women, cisgender women and cisgender men over 12 months.Vertical jump heights (cm) will be evaluated using two different techniques - the jump with a static start at 90° of knee flexion for \~2s before the jump, and another free jump to make the descent movement and vertical impulse with leg extension. The depth of the countermovement will be determined by the participant himself, in order to avoid alterations in the coordination of the jump. All jumps must be performed with hands on hips and participants will be instructed to jump as high as possible. The jumping mat (Elite Jump®, S2 Sports, São Paulo, Brazil) will be used. A total of five attempts will be allowed for each jump, spaced by 15 second intervals. The highest height for each modality will be used for future analyses.

    Time frame: Baseline, 6 months, 12 months after starting the observational study.

  4. Speed changes of transgender women over 12 months assessed by 20-meter run with change of direction (Zig-Zag Test).

    The comparison of changes of speed during sprint of transgender women, cisgender women and cisgender men over 12 months.Participants will be instructed to fast for at least 2 hours before the test, following the dietary recommendations described for the maximal effort test. Before the start of the tests, participants will be asked to perform a warm-up protocol including running for 10 minutes of light to moderate intensity, followed by 3 minutes of active lower limb stretching. We will use the 20-meter run with change of direction (Zig-Zag Test). There will be 3 changes of direction with cones at 100° of angulation. The average duration of execution of this test by trained individuals ranges between 5 and 6 seconds. Photocells will be used to start and stop the timer, in order to increase the accuracy of the test. Participants will take the test in 3 attempts, with a 15-minute break between them, for equipment adjustments and rest.

    Time frame: Baseline, 6 months, 12 months after starting the observational study.

  5. Heart rate change of transgender women over 12 months assessed by frequency meter (Polar®) during cardiopulmonary exercise testing

    The comparison of changes in heart rate capacity of transgender women, cigender women and cisgender men submitted to maximum effort Participants will be submitted to cardiopulmonary exercise testing (K5 - COSMED, Italia) on a treadmill (MOVEMENT/ET20 RT250G2SAC110V ) with incremental effort until exhaustion (ramp protocol. Heart rate will be continuously evaluated through frequency meter (Polar®).

    Time frame: Baseline, 6 months, 12 months after starting the observational study.

  6. Percentage of body fat mass (%FM) change of transgender women over 12 months assessed by a densitometry device (GE Prodigy).

    The comparison of changes in percentage of body fat mass (%FM), of transgender women, cisgender women and cisgender men over 12 months. Muscle mass will be assessed by a densitometry device (GE Prodigy) with X-ray absorptiometry technique with two whole-body energy levels and analyzed in the corresponding manufacturer's software.

    Time frame: Baseline, 6 months, 12 months after starting the observational study.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — No sharing will be done.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05337865
Lead sponsor
Instituto Brasileiro de Controle do Cancer
Responsible party
Leonardo Alvares (Medical Technical Director, Instituto Brasileiro de Controle do Cancer) — Principal investigator
First posted
Apr 20, 2022
Start date
May 2022 (estimated)
Primary completion
Aug 2022 (estimated)
Completion
Jun 2023 (estimated)
Last update
Apr 20, 2022

Study contacts

Leonardo Alvares, MD
Contact
leo_a_alvares@yahoo.com.br
5511963676263
Raphael Einsfeld, Phd
Contact
raphaeleinsfeld@gmail.com
5511987774499

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion